ANAB AnaptysBio, Inc.
Legal ·
AnaptysBio sued TESARO, Inc. and GSK on Nov. 20, 2025 over the dostarlimab collaboration. Trial ended July 17, 2026, and post-trial argument is set for Oct. 20. Tesaro's claim that AnaptysBio breached its duties was dismissed April 24.
AnaptysBio completed the spin-off of First Tracks Biotherapeutics on April 20, 2026, one share for every share held on April 6. AnaptysBio keeps the royalty business and gives a range of $140-$145 million for its net cash, while the press release calls the spin-off taxable and cites an EBIT margin it does not reconcile to GAAP.
Shareholders received one First Tracks share for each AnaptysBio share held on April 6, 2026. AnaptysBio now manages two royalty collaborations and starts with about $140-$145 million in net cash.
AnaptysBio will spin off First Tracks Bio on April 20, 2026 with $180 million of cash, $100 million of it from AnaptysBio itself, and the release gives no results for the spun-off company's lead programs.
AnaptysBio's Verified Complaint of Nov 20, 2025 names Tesaro, Inc. and its parent GlaxoSmithKline and alleges breaches of the Jemperli collaboration. Tesaro sued AnaptysBio the same day, and the parties have agreed to ask for an expedited schedule.
AnaptysBio's new shelf replaces one that expires January 11, 2025, and its $100,000,000 sales program with TD Securities (USA) LLC could sell up to 4,819,277 shares at $20.75 each, with immediate dilution of $15.59 per share for new buyers.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $234.6 million | $91.3 million |
| Net income (loss) | -$13.2 million | -$145.2 million |
| Cash from operations | $19.7 million | -$135.3 million |
| Cash and equivalents | $238.2 million | $123.1 million |
| Short-term investments | $73.4 million | $262.3 million |
Our latest story on this, dated Sep 21, 2026: "AnaptysBio awaits post-trial argument in Delaware suit against GSK and Tesaro". The story links the filing or release it is based on. Read the story.
AnaptysBio, Inc. trades under the ticker ANAB on NASDAQ.
AnaptysBio, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:AN6; LSE:0HFQ.
The SEC Central Index Key (CIK) for AnaptysBio, Inc. is 1370053. Its filings are on SEC EDGAR.
29,100,902 shares as of 2026-05-07, per the cover page of its 10-Q filed 2026-05-12.
Our directory records AnaptysBio, Inc. under United States.
Our directory classifies AnaptysBio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for AnaptysBio, Inc. is US0327241065.
aibio.space lists AnaptysBio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$234.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
AnaptysBio, Inc. reported a net loss of $13.2 million for the fiscal year ended Dec 31, 2025, and generated $19.7 million of cash from operations, per its annual report to the SEC.
$286.5 million in cash and short-term investments at Mar 31, 2026, per its 10-Q.
Our latest story on AnaptysBio, dated Sep 21, 2026: "AnaptysBio awaits post-trial argument in Delaware suit against GSK and Tesaro". AnaptysBio sued TESARO, Inc. and GSK on Nov. 20, 2025 over the dostarlimab collaboration. Trial ended July 17, 2026, and post-trial argument is set for Oct. 20. Tesaro's claim that AnaptysBio breached its duties was dismissed April 24. Source.
Our latest financing story, dated Mar 27, 2026: "AnaptysBio board approves First Tracks spin-off, set to launch with $180 million". AnaptysBio will spin off First Tracks Bio on April 20, 2026 with $180 million of cash, $100 million of it from AnaptysBio itself, and the release gives no results for the spun-off company's lead programs. Source.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio